Progress in Medical Research

Progress in Medical Research

Sale price  £73.49 Regular price  £97.99
Skip to product information
Progress in Medical Research

Progress in Medical Research

Government Programs and Key Issues

Written by Nima Gustavsson

Sale price  £73.49 Regular price  £97.99
Only a few left
During the 115th Congress, several bipartisan bills were introduced that aimed to expand the number of telehealth services that are covered under Medicare. Telehealth is the electronic delivery of a health care service via a technological method. Health care providers use telehealth to improve patients access to and quality of care. Under Medicare, these patients are likely to live in rural areas, be under the age of 65 and be disabled. The first chapter in this book examines legislation as it relates to expanding telehealth services, including the five conditions that a telehealth service must meet to be covered and paid for under Medicare Part B. The second chapter focuses on the background and key issues surrounding biologics and biosimilars. Biologics and biosimilars frequently require special handling (such as refrigeration) and processing to avoid contamination by microbes and other unwanted substances. Also, they are usually administered to patients via injection or infused directly into the bloodstream. For these reasons, biologics often are referred to as specialty drugs. The cost of specialty drugs, including biologics, can be extremely high. The next chapter is a two-page report on a recent experiment in the United States using the gene modification tool CRISPR to target a disease gene in human embryos which raised optimism about promising medical advances, generated scientific debate as well as renewed debate about longstanding ethical issues. The fourth chapter provides a brief history of FDA drug regulation, describes FDAs early risk management programs, and focuses on the agencys current risk management authorities, specifically risk evaluation and mitigation strategies (REMS). The chapter also discusses issues that have arisen as a result of REMS, particularly the impact on generic drug competition. The last chapter of this book addresses frequently asked questions about government and private-sector policies that affect drug prices and availability. Among the prescription drug topics covered are federally funded research and development, regulation of direct-to-consumer advertising, legal restrictions on reimportation and federal price negotiation.
ISBN-13
9781536141054
Publication date
4 October 2018
Format
Paperback
Pages
107
Dimensions
230 x 155 mm
Language
English

More in Medicine: general

My Child Is Sick!
Paperback

My Child Is Sick!

Barton D Schmitt, MD, Barton D Schmitt and MD

£11.96

Health and Health Care Inequities
Paperback

Health and Health Care Inequities

Arnel M. Borras

£14.96

About Canada: Dental Care
Paperback

About Canada: Dental Care

Brandon Doucet

£12.71

Got Blood to Give
Paperback

Got Blood to Give

OmiSoore H. Dryden

£16.46

About Canada: Health and Illness, 3rd Edition
Paperback

About Canada: Health and Illness, 3rd Edition

Dennis Raphael

£12.71

Lawless
Paperback

Lawless

Martha Paynter

£15.71